Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJN5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $15,727
Award facts
- Contract value 100% obligated
- $15,726.96 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) issued a delivery order valued at $15,726.96 to DMS Pharmaceutical Group Inc. for XOLAIR 300 mg/2 mL auto-injector vials on January 21, 2026, with delivery due by February 11, 2026. This delivery order was awarded on a firm fixed-price basis without set-aside designation, leveraging DMS Pharmaceutical Group's established position as a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois. The award stems from DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) under the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion federal acquisition strategy designed to support recurring pharmaceutical supply needs across the Department of Defense's global military healthcare system.
DMS Pharmaceutical Group Inc., a long-standing federal contractor registered in the System for Award Management since 2001, maintains an extensive pharmaceutical product portfolio encompassing branded and generic prescription medications, biologics, vaccines, and specialty pharmaceuticals. The company's primary IDC with the DLA, awarded in November 2025 with a $499.999 billion ceiling value and completion date of December 31, 2036, positions it as a critical regional prime vendor contractor authorized to supply diverse pharmaceutical products to military medical facilities worldwide. This particular delivery order for XOLAIR, a biologic immunosuppressant, exemplifies the specialized pharmaceutical requirements that DMS Pharmaceutical Group fulfills through its established performance under the broader PPV-G GEN V framework.
Quick answers
Who was awarded contract SPE2DR26FDJN5?
SPE2DR26FDJN5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 21, 2026.
How much is contract SPE2DR26FDJN5 worth?
The government has obligated $15,727 on SPE2DR26FDJN5.
Is contract SPE2DR26FDJN5 an order under another contract?
Yes. SPE2DR26FDJN5 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJN5 competed?
The extent of competition for SPE2DR26FDJN5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award